Pfizer has started phase II trials of a candidate drug to treat Duchenne muscular dystrophy (DMD) as it plays catch-up with rivals PTC Therapeutics, Prosensa and Sarepta. The pharma giant has ...

The company is developing treatments for autism and substance use disorders tailored to patient subgroups identified by clinico-genomic signatures.